Clinical trials: G-CSF
Multiple Myeloma, Autologous Transplantation
Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3102 protocol (NCT00103662).
- Trial name
- NCT00741780
- Testing
- plerixafor, granulocyte colony-stimulating factor (G-CSF)
- Volunteers
- 164 people
- Sponsor
- Genzyme, a Sanofi Company
Sarcoma, Neutropenia
Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy
Physicians are conducting a clinical trial for patients with pediatric sarcoma. Sarcoma is a type of bone cancer that can be treated with chemotherapy which can affect the bone marrow, where blood cells are produced.
- Trial name
- NCT00035620
- Testing
- pegfilgrastim, filgrastim
- Volunteers
- 44 people
- Sponsor
- Amgen
Non-Hodgkin's Lymphoma, Autologous Transplantation
Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).
This is a long-term observational study of patients that were treated with at least 1 dose of study treatment (plerixafor or placebo) in the AMD3100-3101 protocol (NCT00103610).
- Trial name
- NCT00741325
- Testing
- granulocyte colony-stimulating factor (G-CSF), plerixafor
- Volunteers
- 178 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumour, Malignant Haematological Tumour
Nivestim™ in Treatment of Malignant Diseases
The purpose of this study is to observe the tolerability, safety and efficacy of preventative treatment using Nivestim™ in patients receiving cytotoxic chemotherapy for cancer.
- Conditions
- Solid Tumour, Malignant Haematological Tumour, Primary or Secondary Prophylactic Treatment
- Trial name
- NCT01627990
- Where
- 48 sites in Germany
- Volunteers
- 386 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
HIV Infections, Cytopenias
A Randomized, Controlled, Multicenter Trial of Filgrastim (Recombinant-Methionyl Human Granulocyte Colony Stimulating Factor; G-CSF) for the Prevention of Grade 4 Neutropenia in Patients With HIV Infection.
To determine, in HIV-infected patients, the efficacy of filgrastim ( recombinant-methionyl human granulocyte-colony stimulating factor; G-CSF ) in preventing grade 4 neutropenia, i.e., absolute neutrophil count (ANC) < 500…
- Trial name
- NCT00002126
- Testing
- Filgrastim
- Where
- 22 sites in United States, Canada
- Volunteers
- 250 people
- Sponsor
- Amgen
Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia
A Study to Investigate the Safety and Tolerability of Granulocyte-colony Stimulating Factor (G-CSF) Dosage Reduction in Mavorixafor-treated Participants With Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders
The purpose of this study is to evaluate the safety and tolerability of G-CSF dosage reduction with mavorixafor in participants with autoimmune neutropenia (AIN) and chronic idiopathic neutropenia (CIN) disorders as assessed by…
- Conditions
- Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders, Chronic Neutropenia, Autoimmune Neutropenia, Chronic Idiopathic Neutropenia
- Trial name
- NCT07902830
- Testing
- Mavorixafor
- Volunteers
- 40 people
- Sponsor
- X4 Pharmaceuticals
Neutropenia
A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement
The purpose of the study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of daily subcutaneous administration of 5 μg/kg tbo-filgrastim in infants, children and adolescents with solid tumors without…
- Trial name
- NCT02190721
- Testing
- tbo-filgrastim
- Where
- 33 sites in United States, Bulgaria and 6 more
- Volunteers
- 50 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Acute Myeloid Leukemia
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
This is a single-center open-label phase I clinical trial of delivering haploidentical natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of ALT-801 in patients with relapsed/refractory Acute…
- Trial name
- NCT01478074
- Testing
- G-CSF, Cytarabine, Fludarabine
- Where
- United States
- Sponsor
- Altor BioScience
Lymphoma, Leukemia
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
The incidence of infectious complications in hematological malignancies is higher than that in children with solid tumors, which may be related to the type and dose intensity of chemotherapy regimens used in hematological tumors.
- Trial name
- NCT04497701
- Testing
- PEG-rhG-CSF group, rhG-CSF group
- Where
- China
- Volunteers
- 139 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Prostate Cancer
Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with G-CSF may make tumor cells more sensitive to the chemotherapy drug and may kill…
- Trial name
- NCT00003183
- Testing
- filgrastim, mitoxantrone hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hope Cancer Institute, Inc.